In contrast to the availability of potent and selective antagonists of several
prostaglandin receptor types (including DP1 , DP2 , EP and
TP receptors), there has been a paucity of well-characterized, selective
FP receptor antagonists. The earliest ones included dimethyl
amide and dimethyl
amine derivatives of PGF2α , but these have failed to gain prominence. The fluorinated PGF2α analogues,
AL-8810 and
AL-3138, were subsequently discovered as competitive and non-competitive
FP receptor antagonists respectively. Non-
prostanoid structures, such as the thiazolidinone
AS604872, the D-
amino acid-based
oligopeptide PDC31 and its peptidomimic analogue PDC113.824 came next, but the latter two are allosteric inhibitors of
FP receptor signalling.
AL-8810 has a sub-micromolar in vitro potency and ≥2 log unit selectivity against most other PG receptors when tested in several cell- and tissue-based functional assays. Additionally,
AL-8810 has demonstrated therapeutic efficacy as an
FP receptor antagonist in animal models of
stroke,
traumatic brain injury,
multiple sclerosis,
allodynia and
endometriosis. Consequently, it appears that
AL-8810 has become the
FP receptor antagonist of choice. LINKED ARTICLES: This article is part of a themed section on
Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc.